ClinicalTrials.gg
CompletedNCT03393377AGE-ZTUpdated Jan 8, 2018

Preventive Arterial Wall Phenotype and Low-dose Fluvastatin/Valsartan Combination

An interventional study of fluvastatin 10 mg and valsartan 20 mg and placebo in Atherosclerosis, sponsored by University Medical Centre Ljubljana. Completed. Open to male participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-08.

Sponsored by University Medical Centre Ljubljana · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Sep 2014, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 55 Years
Sex
Male
01

Study summary

The study was designed to test whether short-term treatment with a very low-dose combination of fluvastatin and valsartan could induce improvement of endothelial function, arterial stiffness, vascular inflammation, oxidative stress and expression of protective genes in subjects with moderate cardiovascular risk.

Read the detailed description

The largest population that suffers from cardiovascular events are subjects at moderate cardiovascular risk. However, no effective and safe preventive treatment is available for this population. This study aimed to investigate whether their arterial wall phenotype could be turned to a preventive direction by low-dose fluvastatin/valsartan combination (low-flu/val).

Twenty males at moderate cardiovascular risk (as classified by SCORE) were blindly randomised into the intervention group (n=10, low-flu/val: 10 mg/20mg) or control group (n=10, placebo). At inclusion and after 30 days of treatment, brachial flow-mediated dilatation (FMD), beta stiffness coefficient, carotid pulse wave velocity (c-PWV), carotid-femoral PWV, reactive hyperaemia index, high-sensitivity C-reactive protein (hs-CRP), interleukin 6, vascular cell adhesion molecule 1, total antioxidant status and expression of several protective genes (SIRT1, mTOR, NF-κB1, NFE2L2, PRKAA1) were followed.

02

Conditions studied

  • Atherosclerosis

Browse trials for

Keywords

  • arterial stiffness
  • endothelial dysfunction
  • fluvastatin
  • valsartan
  • inflammatory markers
  • oxidative stress
  • SIRT1
03

In context

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

This study's enrollment of 20 is below the median of 100 across 881 interventional studies indexed under Atherosclerosis.

Browse Atherosclerosis studies →

Lead sponsor

University Medical Centre Ljubljana is the lead sponsor of 296 studies on the registry; 72 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • moderate cardiovascular risk according to Systematic Coronary Risk Estimation (SCORE) risk charts of the European Society of Cardiology
  • males
  • aged between 40 and 55 years

Exclusion criteria

Exclusion Criteria:

  • diabetes mellitus
  • manifest peripheral artery disease or carotid artery disease
  • acute infection
  • chronic diseases
  • present therapy with fluvastatin and/or valsartan
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    intervention group

    received fluvastatin 10 mg and valsartan 20 mg (low-flu/val) for 30 days

    Drug: fluvastatin 10 mg and valsartan 20 mg

  • Placebo comparator
    control group

    received placebo for 30 days

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. brachial flow-mediated dilatation (FMD)

    FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)

    Time frame: 30 days

  2. reactive hyperaemia index (RHI)

    RHI measured by Endopat device

    Time frame: 30 days

  3. beta stiffness coefficient

    assessed by ultrasound employing e-Tracking on right common carotid artery

    Time frame: 30 days

  4. carotid pulse wave velocity (c-PWV)

    assessed by ultrasound employing e-Tracking on right common carotid artery

    Time frame: 30 days

  5. carotid-femoral PWV (cf-PWV)

    cf-PWV measured by Sphygmocor device

    Time frame: 30 days

  6. high-sensitivity C-reactive protein (hs-CRP)

    inflammatory marker

    Time frame: 30 days

  7. interleukin 6 (IL-6)

    inflammatory marker

    Time frame: 30 days

  8. vascular cell adhesion molecule 1 (VCAM1)

    inflammatory marker

    Time frame: 30 days

  9. total antioxidant status (TAS)

    marker of oxidative stress

    Time frame: 30 days

  10. gene SIRT1

    Hs01009006_m1

    Time frame: 30 days

  11. gene mTOR

    Hs00234522_m1

    Time frame: 30 days

  12. gene NF-kB1

    Hs00765730_m1

    Time frame: 30 days

  13. gene Nrf2/NFE2L2

    Hs00975961_g1

    Time frame: 30 days

  14. gene AMPK/PRKAA1

    Hs01562315_m1

    Time frame: 30 days

Secondary outcomes

  1. brachial flow-mediated dilatation (FMD)

    FMD measured by ultrasound on right brachial artery (as result of reactive hyperaemia)

    Time frame: 10 weeks after treatment completion

  2. reactive hyperaemia index (RHI)

    RHI measured by Endopat device

    Time frame: 10 weeks after treatment completion

  3. beta stiffness coefficient

    assessed by ultrasound employing e-Tracking on right common carotid artery

    Time frame: 10 weeks after treatment completion

  4. carotid pulse wave velocity (c-PWV)

    assessed by ultrasound employing e-Tracking on right common carotid artery

    Time frame: 10 weeks after treatment completion

  5. carotid-femoral PWV (cf-PWV)

    cf-PWV measured by Sphygmocor device

    Time frame: 10 weeks after treatment completion

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S; ESC Scientific Document Group. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-2381. doi: 10.1093/eurheartj/ehw106. Epub 2016 May 23. No abstract available. PubMed 27222591 ↗
  • Matsuzawa Y, Kwon TG, Lennon RJ, Lerman LO, Lerman A. Prognostic Value of Flow-Mediated Vasodilation in Brachial Artery and Fingertip Artery for Cardiovascular Events: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2015 Nov 13;4(11):e002270. doi: 10.1161/JAHA.115.002270. PubMed 26567372 ↗
  • Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. PubMed 20338492 ↗
  • Paneni F, Diaz Canestro C, Libby P, Luscher TF, Camici GG. The Aging Cardiovascular System: Understanding It at the Cellular and Clinical Levels. J Am Coll Cardiol. 2017 Apr 18;69(15):1952-1967. doi: 10.1016/j.jacc.2017.01.064. PubMed 28408026 ↗
  • Lunder M, Janic M, Jug B, Sabovic M. The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial. Eur J Intern Med. 2012 Apr;23(3):261-6. doi: 10.1016/j.ejim.2011.11.011. Epub 2011 Dec 12. PubMed 22385885 ↗
  • Boncelj Svetek M, Erzen B, Kanc K, Sabovic M. Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan. J Diabetes Complications. 2017 Mar;31(3):544-550. doi: 10.1016/j.jdiacomp.2016.12.002. Epub 2016 Dec 16. PubMed 28012835 ↗
  • Janic M, Lunder M, Prezelj M, Sabovic M. A combination of low-dose fluvastatin and valsartan decreases inflammation and oxidative stress in apparently healthy middle-aged males. J Cardiopulm Rehabil Prev. 2014 May-Jun;34(3):208-12. doi: 10.1097/HCR.0000000000000027. PubMed 24263076 ↗
  • Sosnowska B, Mazidi M, Penson P, Gluba-Brzozka A, Rysz J, Banach M. The sirtuin family members SIRT1, SIRT3 and SIRT6: Their role in vascular biology and atherogenesis. Atherosclerosis. 2017 Oct;265:275-282. doi: 10.1016/j.atherosclerosis.2017.08.027. Epub 2017 Aug 26. PubMed 28870631 ↗
  • Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, Lopez-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. PubMed 27040132 ↗
  • Robinson JG, Gidding SS. Curing atherosclerosis should be the next major cardiovascular prevention goal. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2779-85. doi: 10.1016/j.jacc.2014.04.009. Epub 2014 May 7. PubMed 24814489 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2014 to primary completion in Jun 2015, 9 months.

Of 178 non-industry interventional studies with no phase under Atherosclerosis, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 56. This study's 9 months is below that.

Counting every sponsor, half of 198 studies reached it within 30 months; a quarter within 17 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2017
First posted
Jan 8, 2018
StartActual
Sep 2014
Primary completionActual
Jun 2015
CompletionActual
Jun 2017
Last update
Jan 8, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03393377
Responsible party
Martina Turk Veselič (Medical Doctor, University Medical Centre Ljubljana) — Principal investigator
First posted
Jan 8, 2018
Start date
Sep 2014
Primary completion
Jun 2015
Completion
Jun 2017
Last update
Jan 8, 2018

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluvastatin

Start the discussion